Antisense strategies for oncogene inactivation

C. A. Stein, Luba Benimetskaya, Sridhar Mani

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Antisense oligonucleotides have been evaluated as antineoplastic agents in a series of clinical trials, with mixed results. However, phase III trials incorporating G3139, a phosphorothioate oligomer targeted to the initiation codon region of the bcl-2 mRNA, have recently been completed in advanced melanoma, myeloma, and chronic lymphocytic leukemia (CLL). This article discusses the mechanism of the antisense effect and its dependence on the cellular internalization of oligonucleotides and the activity of RNase H. It also describes the properties, specific and nonspecific, of phosphorothioate oligonucleotides, the predominant species in current clinical trials, and discusses pharmacokinetic data obtained from earlier phase I and II trials employing these molecules. While the application of antisense technology to the treatment of human cancer is conceptually straightforward, in practice there are many complicated, mechanistically based questions that must be considered.

Original languageEnglish (US)
Pages (from-to)563-572
Number of pages10
JournalSeminars in Oncology
Volume32
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Oncogenes
Phosphorothioate Oligonucleotides
Clinical Trials
Ribonuclease H
Initiator Codon
Antisense Oligonucleotides
B-Cell Chronic Lymphocytic Leukemia
Oligonucleotides
Antineoplastic Agents
Melanoma
Pharmacokinetics
Technology
Messenger RNA
Neoplasms
oblimersen

ASJC Scopus subject areas

  • Oncology

Cite this

Antisense strategies for oncogene inactivation. / Stein, C. A.; Benimetskaya, Luba; Mani, Sridhar.

In: Seminars in Oncology, Vol. 32, No. 6, 12.2005, p. 563-572.

Research output: Contribution to journalArticle

Stein, C. A. ; Benimetskaya, Luba ; Mani, Sridhar. / Antisense strategies for oncogene inactivation. In: Seminars in Oncology. 2005 ; Vol. 32, No. 6. pp. 563-572.
@article{45ea13a063dd459e84fd35e304cd6495,
title = "Antisense strategies for oncogene inactivation",
abstract = "Antisense oligonucleotides have been evaluated as antineoplastic agents in a series of clinical trials, with mixed results. However, phase III trials incorporating G3139, a phosphorothioate oligomer targeted to the initiation codon region of the bcl-2 mRNA, have recently been completed in advanced melanoma, myeloma, and chronic lymphocytic leukemia (CLL). This article discusses the mechanism of the antisense effect and its dependence on the cellular internalization of oligonucleotides and the activity of RNase H. It also describes the properties, specific and nonspecific, of phosphorothioate oligonucleotides, the predominant species in current clinical trials, and discusses pharmacokinetic data obtained from earlier phase I and II trials employing these molecules. While the application of antisense technology to the treatment of human cancer is conceptually straightforward, in practice there are many complicated, mechanistically based questions that must be considered.",
author = "Stein, {C. A.} and Luba Benimetskaya and Sridhar Mani",
year = "2005",
month = "12",
doi = "10.1053/j.seminoncol.2005.09.003",
language = "English (US)",
volume = "32",
pages = "563--572",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Antisense strategies for oncogene inactivation

AU - Stein, C. A.

AU - Benimetskaya, Luba

AU - Mani, Sridhar

PY - 2005/12

Y1 - 2005/12

N2 - Antisense oligonucleotides have been evaluated as antineoplastic agents in a series of clinical trials, with mixed results. However, phase III trials incorporating G3139, a phosphorothioate oligomer targeted to the initiation codon region of the bcl-2 mRNA, have recently been completed in advanced melanoma, myeloma, and chronic lymphocytic leukemia (CLL). This article discusses the mechanism of the antisense effect and its dependence on the cellular internalization of oligonucleotides and the activity of RNase H. It also describes the properties, specific and nonspecific, of phosphorothioate oligonucleotides, the predominant species in current clinical trials, and discusses pharmacokinetic data obtained from earlier phase I and II trials employing these molecules. While the application of antisense technology to the treatment of human cancer is conceptually straightforward, in practice there are many complicated, mechanistically based questions that must be considered.

AB - Antisense oligonucleotides have been evaluated as antineoplastic agents in a series of clinical trials, with mixed results. However, phase III trials incorporating G3139, a phosphorothioate oligomer targeted to the initiation codon region of the bcl-2 mRNA, have recently been completed in advanced melanoma, myeloma, and chronic lymphocytic leukemia (CLL). This article discusses the mechanism of the antisense effect and its dependence on the cellular internalization of oligonucleotides and the activity of RNase H. It also describes the properties, specific and nonspecific, of phosphorothioate oligonucleotides, the predominant species in current clinical trials, and discusses pharmacokinetic data obtained from earlier phase I and II trials employing these molecules. While the application of antisense technology to the treatment of human cancer is conceptually straightforward, in practice there are many complicated, mechanistically based questions that must be considered.

UR - http://www.scopus.com/inward/record.url?scp=28844454167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844454167&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2005.09.003

DO - 10.1053/j.seminoncol.2005.09.003

M3 - Article

C2 - 16338422

AN - SCOPUS:28844454167

VL - 32

SP - 563

EP - 572

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6

ER -